The gastrin-releasing peptide receptor in prostate cancer

In this review, researchers have described the potential applications of the gastrin-releasing peptide receptor in the diagnosis, prognosis and treatment of prostate cancer. The interest of this receptor is also described for other types of solid tumors. For the researchers, this receptor could be of at least equal interest to that of PSA, used in current clinical practice. The development of therapies based on antagonists of this receptor could be an innovative therapeutic approach in prostate cancer. In terms of diagnosis, this receptor could enable the detection of low-grade prostate cancer, with the detection of negative lesions with existing tests.